Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug shows promise for rare muscle disease in early trial

NCT ID NCT05669014

First seen Nov 03, 2025 · Last updated May 21, 2026 · Updated 30 times

Summary

This study tested an investigational drug called daxdilimab in 12 adults with dermatomyositis or anti-synthetase myositis that was not well controlled by standard treatments. Participants received either daxdilimab or a placebo to see if the drug could reduce disease activity and skin symptoms over 24 weeks. The goal is to find a safer, more effective option for managing these rare inflammatory muscle diseases.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC INFLAMMATORY MYOSITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Accelerium, S. de R.L. de C.V. - PPDS

    Monterrey, 64000, Mexico

  • Advanced Research Center, Inc.

    Anaheim, California, 92805-5854, United States

  • Aintree University Hospital - NWCRN - PPDS

    Liverpool, Merseyside, L9 7AL, United Kingdom

  • Centro Mineiro de Pesquisa - CMiP

    Juiz de Fora, Minas Gerais, 36010-570, Brazil

  • Hospital Quironsalud Infanta Luisa

    Seville, 41010, Spain

  • LMK Servicos Medicos SS

    Porto Alegre, Rio Grande do Sul, 90480-000, Brazil

  • Revmatologicky ustav

    Prague, Praha, Hlavní Mesto, 128 00, Czechia

  • Unidad de Investigacion de las Enfermedades Reumaticas S.A. De C.V.

    Mexico City, Mexico

  • Western General Hospital Edinburgh - PPDS

    Edinburgh, Midlothian, EH4 2XU, United Kingdom

Conditions

Explore the condition pages connected to this study.